Corvus Pharmaceuticals (CRVS)

• Market cap: $315M
• 1 day: 7.69%
• 5 days: -2.00%
• 1 month: -45.13%
• 3 months: -5.41%
• 6 months: 167.76%
• Year to date: 178.41%
• 1 year: 184.88%
• 5 years: 7.22%
• 10 years: -65.61%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 28

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,029% more call options, than puts

Call options by funds: $6.07M | Put options by funds: $538K

280% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 5

211% more capital invested

Capital invested by funds: $50.9M [Q2] → $158M (+$107M) [Q3]

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

30% more funds holding

Funds holding: 47 [Q2] → 61 (+14) [Q3]

3.3% more ownership

Funds ownership: 44.71% [Q2] → 48.0% (+3.3%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $14 186% upside
• Avg. target: $14 186% upside
• High target: $14 186% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Jeff Jones 24% 1-year accuracy 10 / 41 met price target

186% upside $14

Outperform Reiterated

13 Nov 2024